A Study for People with Metastatic Colorectal Cancer (Stage IV) - INCA33890

Overview

This fact sheet explains the study, "A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer."

(ClinicalTrials.gov Identifier: NCT07284849).

Who can take part?  

You may be able to participate if you:

• Are 18 years or older
• Have stage IV metastatic colorectal cancer
• Have not received prior treatment for metastatic disease (this is first-line treatment)
• Are confirmed to have microsatellite stable (MSS) disease
• Are physically well enough for treatment
• Have cancer that can be measured on imaging scans

Please download the clinical trials fact sheet for more information about this trial.

‍